Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review
- 20 July 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Neural Transmission
- Vol. 129 (10), 1247-1256
- https://doi.org/10.1007/s00702-022-02529-x
Abstract
Anecdotal references, preclinical, and non-randomized studies support the therapeutic potential of cannabinoids for movement disorders (MD). To create an evidenced-based point of view for patients and physicians, we performed a systematic review of randomized controlled trials (RCT) on the use of cannabinoids in MD. The seven RCTs found on PD used different cannabis formulations. No improvement of motor symptoms was shown in any of the two RCTs with this as primary outcome (PO), but in the nabilone group, an improvement in quality of life was documented. Of the three RCTs having levodopa-induced dyskinesia as PO, only one using nabilone showed a reduction. Anxiety and anxiety-induced tremor could be reduced in the cannabidiol group as well as anxiety and sleeping problems in the nabilone group in another RCT. In two RCTs with Tourette syndrome, an improvement in tics was revealed. From three RCTs on Huntington’s disease only one found symptoms relief using nabilone. No reduction of dystonia could be shown in the two included RCTs. The limited number of available but small and inhomogeneous RCTs precludes reliable conclusions. Therefore, more and smartly designed RCTs are urgently needed.Keywords
This publication has 55 references indexed in Scilit:
- Systematic review: Efficacy and safety of medical marijuana in selected neurologic disordersNeurology, 2014
- Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trialBasal Ganglia, 2011
- Sativex®(tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical dataExpert Review of Neurotherapeutics, 2011
- Cannabinoids for Tourette's SyndromeEmergencias, 2009
- Huntington's DiseaseSeminars in Neurology, 2007
- Huntington's diseaseThe Lancet, 2007
- Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette SyndromeBritish Journal of Psychology, 2003
- Treatment of Tourette Syndrome with Delta-9-Tetrahydrocannabinol (Δ9-THC): No Influence on Neuropsychological PerformanceNeuropsychopharmacology, 2003
- Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover TrialPharmacopsychiatry, 2002
- Controlled clinical trial of cannabidiol in Huntington's diseasePharmacology Biochemistry and Behavior, 1991